ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 5, 2008
ACADIA to Host Conference Call and Webcast on Wednesday, March 5, 2008, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the fourth quarter and year ended December 31, 2007 on Wednesday, March 5, 2008, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Wednesday, March 5, 2008, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.
The conference call may be accessed by dialing 866-713-8563 for participants in the U.S. or Canada and 617-597-5311 for international callers (reference passcode 19968971). A telephone replay of the conference call may be accessed through March 19, 2008 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 33515453). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until March 19, 2008.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five mid-to-late stage clinical programs as well as a portfolio of preclinical and discovery assets directed at diseases with large unmet medical needs, including schizophrenia, Parkinson's disease psychosis, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial